Heart failure & cardiomyopathies
Vericiguat in advanced heart failure patients receiving chronic intermittent levosimendan infusions: a prospective pilot study
Authors' conclusion
This study provides the first prospective evidence supporting the safe use of vericiguat in AdHF patients on chronic levosimendan.
Study context
- Population
- Advanced heart failure (HF) patients receiving monthly levosimendan infusions
- Participants
- 18 patients
- Exposure
- Vericiguat-eligible vs non-eligible patients
- Eligiblen = 8
- Outcome
- Safety and tolerability of vericiguat
Methodological detailssingle-centre
- Single-centre
Main finding
As reported in the abstract
Safety and tolerability
- Vericiguat generally well tolerated; no severe adverse effects observed
Observational data: associations, not effects.
Further findings
- Better echocardiographic findings, improved quality of life and lower 1-year mortality with vericiguat vs non-eligible patients
Safety
- Discontinuation due to symptomatic hypotension — Eligible
- 37.5%
Original publication
Vericiguat in advanced heart failure patients receiving chronic intermittent levosimendan infusions: a prospective pilot study. Heart. Published 14 July 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →